MRNA vs MSTR

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 07, 2026

MRNA

39.1
AI Score
VS
MRNA Wins

MSTR

30.9
AI Score

Investment Advisor Scores

MRNA

39score
Recommendation
EXTENDED

MSTR

31score
Recommendation
EXTENDED

AI Analyst Insights

Detailed Metrics Comparison

Metric MRNA MSTR Winner
Forward P/E 23.0415 3.3693 MSTR
PEG Ratio 0 2.8502 Tie
Revenue Growth 2.1% 6.9% MSTR
Earnings Growth -85.1% -77.5% MSTR
Tradestie Score 39.1/100 30.9/100 MRNA
Profit Margin -141.4% 0.0% MSTR
Beta 1.00 1.00 Tie
AI Recommendation EXTENDED EXTENDED Tie

Relative Price Performance (Last 90 Days)

MRNA 1M: +40.0% · 3M: +156.6% MSTR 1M: +12.3% · 3M: +63.4%

Current Technical Phase

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (49.6% over 20 days), RSI 64

RSI (14): 63.6 · Price: $196.48

MSTR

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (21.0% over 20 days), RSI 55

RSI (14): 55.1 · Price: $153.37

Fundamentals Snapshot

Metric MRNA MSTR
Market Cap — —
Forward P/E -41.0 11.4
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin -0.7% 0.7%
Operating Margin -5.6% -68.1%
EPS -7.36 -99.08
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, MRNA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.